Symbols / URGN $18.73 +1.57%
URGN Chart
About
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 911.82M |
| Enterprise Value | 921.45M | Income | -153.49M | Sales | 109.79M |
| Book/sh | -2.18 | Cash/sh | 2.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 291 | IPO | — |
| P/E | — | Forward P/E | 20.30 | PEG | — |
| P/S | 8.31 | P/B | -8.59 | P/C | — |
| EV/EBITDA | -7.40 | EV/Sales | 8.39 | Quick Ratio | 3.31 |
| Current Ratio | 4.01 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.19 | EPS next Y | 0.92 | EPS Growth | — |
| Revenue Growth | 54.00% | Earnings | 2026-05-12 | ROA | -32.10% |
| ROE | — | ROIC | — | Gross Margin | 88.66% |
| Oper. Margin | -50.52% | Profit Margin | -139.81% | Shs Outstand | 48.68M |
| Shs Float | 38.66M | Short Float | 16.72% | Short Ratio | 11.79 |
| Short Interest | — | 52W High | 30.00 | 52W Low | 3.42 |
| Beta | 1.37 | Avg Volume | 760.81K | Volume | 755.85K |
| Target Price | $35.62 | Recom | Strong_buy | Prev Close | $18.44 |
| Price | $18.73 | Change | 1.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$35.63
Mean price target
2. Current target
$18.73
Latest analyst target
3. DCF / Fair value
$-36.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.73
Low
$16.00
High
$55.00
Mean
$35.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | main | D. Boral Capital | Buy → Buy | $33 |
| 2026-01-23 | main | D. Boral Capital | Buy → Buy | $33 |
| 2026-01-05 | main | D. Boral Capital | Buy → Buy | $33 |
| 2025-10-27 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-10-27 | main | D. Boral Capital | Buy → Buy | $25 |
| 2025-10-03 | main | D. Boral Capital | Buy → Buy | $25 |
| 2025-08-19 | init | Piper Sandler | — → Overweight | $36 |
| 2025-08-11 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-08-07 | main | D. Boral Capital | Buy → Buy | $25 |
| 2025-08-05 | main | D. Boral Capital | Buy → Buy | $25 |
| 2025-07-08 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-07-07 | main | D. Boral Capital | Buy → Buy | $25 |
| 2025-06-16 | up | HC Wainwright & Co. | Neutral → Buy | $50 |
| 2025-06-13 | main | Scotiabank | Sector Outperform → Sector Outperform | $47 |
| 2025-06-13 | main | Guggenheim | Buy → Buy | $30 |
| 2025-06-13 | main | Oppenheimer | Outperform → Outperform | $31 |
| 2025-06-12 | main | D. Boral Capital | Buy → Buy | $25 |
| 2025-06-03 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2025-05-23 | main | Guggenheim | Buy → Buy | $15 |
| 2025-05-22 | main | Goldman Sachs | Neutral → Neutral | $3 |
- URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill hu, 12 Mar 2026 07
- Bladder cancer survey: 80% of patients live with fear it will return - Stock Titan Fri, 13 Mar 2026 12
- UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha hu, 05 Mar 2026 08
- $URGN stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat ue, 03 Mar 2026 08
- Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Mon, 02 Mar 2026 08
- UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st Fri, 05 Dec 2025 08
- URGN: Analyst Maintains Buy Rating with $33 Target | URGN Stock News - GuruFocus Mon, 02 Mar 2026 16
- UroGen grants 51,200 stock units to new hires backing cancer drugs - Stock Titan Fri, 06 Mar 2026 08
- UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha ue, 25 Nov 2025 08
- Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance Wed, 31 Dec 2025 08
- $URGN stock is up 16% today. Here's what we see in our data. - Quiver Quantitative hu, 06 Nov 2025 08
- Bladder cancer trial: ZUSDURI keeps many patients recurrence-free for 2 years - Stock Titan Fri, 27 Feb 2026 08
- A Look At UroGen Pharma (URGN) Valuation After New Phase 3 ENVISION ZUSDURI Data - Yahoo Finance Fri, 27 Feb 2026 08
- New bladder cancer drug helps drive 21% jump in UroGen sales - Stock Titan Mon, 02 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7373 | 145174.0 | — | Sale at price 19.69 per share. | SCHOENBERG MARK | Officer | — | 2026-02-03 00:00:00 | D |
| 1 | 7479 | 147262.0 | — | Sale at price 19.69 per share. | SMITH JASON DREW | General Counsel | — | 2026-02-03 00:00:00 | D |
| 2 | 13333 | nan | — | — | SCHOENBERG MARK | Officer | — | 2026-01-30 00:00:00 | D |
| 3 | 15500 | nan | — | — | SMITH JASON DREW | General Counsel | — | 2026-01-30 00:00:00 | D |
| 4 | 2000 | nan | — | — | BUTITTA CYNTHIA M | Director | — | 2025-11-26 00:00:00 | D |
| 5 | 2000 | nan | — | — | ROBINSON JAMES A JR. | Director | — | 2025-11-26 00:00:00 | D |
| 6 | 2000 | nan | — | — | HOLDEN STUART M.D. | Director | — | 2025-11-26 00:00:00 | D |
| 7 | 2000 | nan | — | — | WEN LEANA | Director | — | 2025-11-26 00:00:00 | D |
| 8 | 2000 | nan | — | — | WILDMAN DANIEL GEORGE | Director | — | 2025-11-26 00:00:00 | D |
| 9 | 10000 | 250000.0 | — | Sale at price 25.00 per share. | SCHOENBERG MARK | Officer | — | 2025-11-19 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -135.66M | -110.33M | -81.90M | -97.77M |
| TotalUnusualItems | -23.41M | -21.55M | -21.56M | -17.29M |
| TotalUnusualItemsExcludingGoodwill | -23.41M | -21.55M | -21.56M | -17.29M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -153.49M | -126.87M | -102.24M | -109.78M |
| ReconciledDepreciation | 2.41M | 1.19M | 1.71M | 1.82M |
| ReconciledCostOfRevenue | 12.45M | 8.88M | 9.36M | 7.65M |
| EBITDA | -135.66M | -110.33M | -81.90M | -97.77M |
| EBIT | -138.07M | -111.52M | -83.61M | -99.59M |
| NetInterestIncome | -27.88M | -27.03M | -33.63M | -29.06M |
| InterestExpense | 15.35M | 12.52M | 14.71M | 8.44M |
| InterestIncome | 5.96M | 8.90M | 2.64M | 938.00K |
| NormalizedIncome | -153.49M | -126.87M | -102.24M | -109.78M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -153.49M | -126.87M | -102.24M | -109.78M |
| TotalExpenses | 234.65M | 187.18M | 148.25M | 143.40M |
| TotalOperatingIncomeAsReported | -124.86M | -96.78M | -65.54M | -79.04M |
| DilutedAverageShares | 48.12M | 42.88M | 28.83M | 22.81M |
| BasicAverageShares | 48.12M | 42.88M | 28.83M | 22.81M |
| DilutedEPS | -3.19 | -2.96 | -3.55 | -4.79 |
| BasicEPS | -3.19 | -2.96 | -3.55 | -4.79 |
| DilutedNIAvailtoComStockholders | -153.49M | -126.87M | -102.24M | -109.78M |
| NetIncomeCommonStockholders | -153.49M | -126.87M | -102.24M | -109.78M |
| NetIncome | -153.49M | -126.87M | -102.24M | -109.78M |
| NetIncomeIncludingNoncontrollingInterests | -153.49M | -126.87M | -102.24M | -109.78M |
| NetIncomeContinuousOperations | -153.49M | -126.87M | -102.24M | -109.78M |
| TaxProvision | 78.00K | 2.83M | 3.92M | 1.75M |
| PretaxIncome | -153.42M | -124.04M | -98.32M | -108.03M |
| OtherIncomeExpense | -670.00K | -229.00K | 838.00K | 72.00K |
| OtherNonOperatingIncomeExpenses | -670.00K | -229.00K | 838.00K | 72.00K |
| GainOnSaleOfSecurity | -23.41M | -21.55M | -21.56M | -17.29M |
| NetNonOperatingInterestIncomeExpense | -27.88M | -27.03M | -33.63M | -29.06M |
| TotalOtherFinanceCost | 18.50M | 23.41M | 21.55M | 21.56M |
| InterestExpenseNonOperating | 15.35M | 12.52M | 14.71M | 8.44M |
| InterestIncomeNonOperating | 5.96M | 8.90M | 2.64M | 938.00K |
| OperatingIncome | -124.86M | -96.78M | -65.54M | -79.04M |
| OperatingExpense | 222.20M | 178.30M | 138.89M | 135.74M |
| ResearchAndDevelopment | 67.11M | 57.15M | 45.61M | 52.91M |
| SellingGeneralAndAdministration | 155.10M | 121.15M | 93.27M | 82.84M |
| GrossProfit | 97.34M | 81.52M | 73.35M | 56.70M |
| CostOfRevenue | 12.45M | 8.88M | 9.36M | 7.65M |
| TotalRevenue | 109.79M | 90.40M | 82.71M | 64.36M |
| OperatingRevenue | 109.79M | 90.40M | 82.71M | 64.36M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 48.35M | 42.23M | 32.49M | 23.13M |
| ShareIssued | 48.35M | 42.23M | 32.49M | 23.13M |
| NetDebt | 11.46M | 3.55M | 42.13M | |
| TotalDebt | 128.33M | 123.39M | 99.39M | 99.12M |
| TangibleBookValue | -105.47M | -8.80M | -65.21M | -89.36M |
| InvestedCapital | 16.74M | 112.93M | 33.34M | 8.18M |
| WorkingCapital | 139.61M | 230.19M | 137.97M | 104.99M |
| NetTangibleAssets | -105.47M | -8.80M | -65.21M | -89.36M |
| CapitalLeaseObligations | 6.12M | 1.65M | 844.00K | 1.59M |
| CommonStockEquity | -105.47M | -8.80M | -65.21M | -89.36M |
| TotalCapitalization | 16.74M | 112.93M | 33.34M | 8.18M |
| TotalEquityGrossMinorityInterest | -105.47M | -8.80M | -65.21M | -89.36M |
| StockholdersEquity | -105.47M | -8.80M | -65.21M | -89.36M |
| GainsLossesNotAffectingRetainedEarnings | 19.00K | 56.00K | 12.00K | -107.00K |
| OtherEquityAdjustments | 19.00K | 56.00K | 12.00K | -107.00K |
| RetainedEarnings | -959.72M | -806.22M | -679.35M | -577.10M |
| AdditionalPaidInCapital | 854.09M | 797.25M | 614.03M | 487.79M |
| CapitalStock | 133.00K | 115.00K | 89.00K | 63.00K |
| CommonStock | 133.00K | 115.00K | 89.00K | 63.00K |
| TotalLiabilitiesNetMinorityInterest | 305.93M | 294.51M | 243.52M | 224.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 259.51M | 248.56M | 212.31M | 201.06M |
| OtherNonCurrentLiabilities | 98.92M | 85.71M | ||
| DerivativeProductLiabilities | 127.28M | 121.39M | 109.72M | 98.92M |
| TradeandOtherPayablesNonCurrent | 3.90M | 3.79M | 3.19M | 3.02M |
| NonCurrentDeferredLiabilities | 3.02M | 2.84M | ||
| NonCurrentDeferredTaxesLiabilities | 3.02M | 2.84M | ||
| LongTermDebtAndCapitalLeaseObligation | 128.33M | 123.39M | 99.39M | 99.12M |
| LongTermCapitalLeaseObligation | 6.12M | 1.65M | 844.00K | 1.59M |
| LongTermDebt | 122.21M | 121.73M | 98.55M | 97.54M |
| CurrentLiabilities | 46.42M | 45.95M | 31.21M | 23.92M |
| OtherCurrentLiabilities | 5.18M | 7.95M | 3.86M | 3.28M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 13.52M | 10.57M | 10.81M | 8.26M |
| PayablesAndAccruedExpenses | 27.72M | 27.43M | 16.54M | 12.38M |
| CurrentAccruedExpenses | 15.58M | 16.50M | 10.02M | 6.86M |
| Payables | 12.14M | 10.93M | 6.51M | 5.53M |
| AccountsPayable | 12.14M | 10.93M | 6.51M | 5.53M |
| TotalAssets | 200.46M | 285.71M | 178.31M | 135.62M |
| TotalNonCurrentAssets | 14.43M | 9.58M | 9.12M | 6.71M |
| OtherNonCurrentAssets | 5.34M | 765.00K | 2.26M | 2.96M |
| InvestmentsAndAdvances | 0.00 | 5.02M | 4.50M | 0.00 |
| InvestmentinFinancialAssets | 0.00 | 5.02M | 4.50M | 0.00 |
| AvailableForSaleSecurities | 5.02M | 4.50M | 675.00K | |
| NetPPE | 9.09M | 3.79M | 2.36M | 3.75M |
| AccumulatedDepreciation | -4.59M | -4.28M | -3.95M | -3.15M |
| GrossPPE | 13.68M | 8.07M | 6.31M | 6.90M |
| Leases | 626.00K | 626.00K | 617.00K | 617.00K |
| OtherProperties | 9.64M | 4.29M | 2.79M | 3.51M |
| MachineryFurnitureEquipment | 3.41M | 3.15M | 2.90M | 2.77M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 186.02M | 276.13M | 169.19M | 128.91M |
| OtherCurrentAssets | 14.67M | 8.85M | 10.28M | 11.10M |
| RestrictedCash | 1.35M | 1.08M | 821.00K | 813.00K |
| PrepaidAssets | 7.48M | |||
| Inventory | 16.46M | 9.23M | 5.67M | 4.33M |
| OtherInventories | -19.00K | 32.00K | 30.00K | -20.00K |
| FinishedGoods | 5.42M | 4.52M | 2.88M | 2.02M |
| RawMaterials | 11.04M | 4.72M | 2.76M | 2.28M |
| Receivables | 33.08M | 20.30M | 15.44M | 12.70M |
| AccountsReceivable | 33.08M | 20.30M | 15.44M | 12.70M |
| CashCashEquivalentsAndShortTermInvestments | 120.46M | 236.69M | 136.97M | 99.96M |
| OtherShortTermInvestments | 9.71M | 64.70M | 41.97M | 44.56M |
| CashAndCashEquivalents | 110.75M | 171.99M | 95.00M | 55.41M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -162.73M | -97.06M | -76.57M | -87.81M |
| RepaymentOfDebt | -1.85M | 0.00 | ||
| IssuanceOfDebt | 0.00 | 24.49M | 0.00 | 95.78M |
| IssuanceOfCapitalStock | 39.80M | 151.17M | 67.36M | 0.00 |
| CapitalExpenditure | -289.00K | -295.00K | -194.00K | -254.00K |
| EndCashPosition | 112.09M | 173.06M | 95.82M | 56.22M |
| BeginningCashPosition | 173.06M | 95.82M | 56.22M | 45.59M |
| ChangesInCash | -60.97M | 77.24M | 39.60M | 10.63M |
| FinancingCashFlow | 39.92M | 194.62M | 116.93M | 97.13M |
| CashFlowFromContinuingFinancingActivities | 39.92M | 194.62M | 116.93M | 97.13M |
| NetOtherFinancingCharges | -160.00K | 72.26M | ||
| ProceedsFromStockOptionExercised | 1.97M | 18.96M | 49.57M | 1.51M |
| NetCommonStockIssuance | 39.80M | 151.17M | 67.36M | 0.00 |
| CommonStockIssuance | 39.80M | 151.17M | 67.36M | 0.00 |
| NetIssuancePaymentsOfDebt | -1.85M | 24.49M | 0.00 | 95.78M |
| NetLongTermDebtIssuance | -1.85M | 24.49M | 0.00 | 95.78M |
| LongTermDebtPayments | -1.85M | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 24.49M | 0.00 | 95.78M |
| InvestingCashFlow | 61.56M | -20.61M | -953.00K | 1.06M |
| CashFlowFromContinuingInvestingActivities | 61.56M | -20.61M | -953.00K | 1.06M |
| NetInvestmentPurchaseAndSale | 61.85M | -20.32M | -759.00K | 1.31M |
| SaleOfInvestment | 139.25M | 107.70M | 49.07M | 64.32M |
| PurchaseOfInvestment | -77.40M | -128.02M | -49.83M | -63.01M |
| NetPPEPurchaseAndSale | -289.00K | -295.00K | -194.00K | -254.00K |
| PurchaseOfPPE | -289.00K | -295.00K | -194.00K | -254.00K |
| OperatingCashFlow | -162.44M | -96.77M | -76.38M | -87.56M |
| CashFlowFromContinuingOperatingActivities | -162.44M | -96.77M | -76.38M | -87.56M |
| ChangeInWorkingCapital | -27.91M | 4.93M | 3.34M | -6.31M |
| ChangeInOtherWorkingCapital | -1.00K | 49.00K | ||
| ChangeInOtherCurrentLiabilities | -729.00K | -237.00K | -811.00K | -1.65M |
| ChangeInOtherCurrentAssets | -4.57M | 1.45M | 702.00K | -1.27M |
| ChangeInPayablesAndAccruedExpense | 3.23M | 10.65M | 6.71M | 1.59M |
| ChangeInAccruedExpense | 2.95M | -244.00K | 2.56M | 1.31M |
| ChangeInPayable | 286.00K | 10.89M | 4.16M | 281.00K |
| ChangeInAccountPayable | 286.00K | 10.89M | 4.16M | 281.00K |
| ChangeInPrepaidAssets | -5.83M | 1.44M | 820.00K | -3.63M |
| ChangeInInventory | -7.24M | -3.55M | -1.35M | -362.00K |
| ChangeInReceivables | -12.78M | -4.86M | -2.74M | -987.00K |
| ChangesInAccountReceivables | -12.78M | -4.86M | -2.74M | -987.00K |
| OtherNonCashItems | 3.60M | -1.30M | 1.01M | 2.62M |
| StockBasedCompensation | 11.96M | 13.11M | 9.34M | 10.58M |
| AmortizationOfSecurities | -1.88M | -2.89M | -1.03M | -498.00K |
| DepreciationAmortizationDepletion | 2.41M | 1.19M | 1.71M | 1.82M |
| DepreciationAndAmortization | 2.41M | 1.19M | 1.71M | 1.82M |
| Depreciation | 2.41M | 1.19M | 1.71M | 1.82M |
| OperatingGainsLosses | 2.87M | 15.08M | 11.50M | 14.01M |
| GainLossOnInvestmentSecurities | 2.87M | 15.08M | 11.50M | 14.01M |
| NetIncomeFromContinuingOperations | -153.49M | -126.87M | -102.24M | -109.78M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for URGN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|